U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H21N3O3.ClH
Molecular Weight 327.806
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESERIDINE HYDROCHLORIDE

SMILES

Cl.CNC(=O)OC1=CC=C2N(C)[C@H]3ON(C)CC[C@@]3(C)C2=C1

InChI

InChIKey=SJOUQRORBYWGNU-SLHAJLBXSA-N
InChI=1S/C15H21N3O3.ClH/c1-15-7-8-17(3)21-13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1H/t13-,15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C15H21N3O3
Molecular Weight 291.3455
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Eseridine (Geneserine) has been known for many years as an anticholinergic agent and used in therapy as a gastrointestinal antispastic. Eseridine salicylate is an inhibitor of cholinesterase activity that has been given by mouth in preparations for dyspepsia and other gastric disorders. It has also been studied for the treatment of Alzheimer’s disease.

Originator

Curator's Comment: Eseridine was first discovered by Eber in 1888 and first obtained in crystal form by Behringer. Merck has stated that eseridine and geneserine, first obtained by Polonovski and Nitzberg in 1915, are identical.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
GENESERINE

Approved Use

Dyspepsia
Doses

Doses

DosePopulationAdverse events​
4.5 mg 3 times / day multiple, oral
Recommended
Dose: 4.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 4.5 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
PubMed

PubMed

TitleDatePubMed
Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
2002-08-15
Geneserine and geneseroline revisited: acid-base catalyzed equilibria of hexahydropyrrolo-[2,3-b]-indole N-oxides with hexahydro-1,2-oxazino-[5,6-b]-indoles.
1989-03-01
[Studies of the effect of geneserine, carbamoyl-choline and acetyl-beta-methyl-choline and other related substances on the thyroid gland of the guinea pig].
1959
[Determination of geneserine in pharmaceutical solutions].
1958-03-01
Patents

Sample Use Guides

Adult: 30 to 45 drops, 3 times a day, preferably taken 1/2 hour before main meals.
Route of Administration: Oral
Geneserine hydrochloride inhibited human Acetylcholinesterase with IC50 value of 100 nM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:11:15 GMT 2025
Edited
by admin
on Mon Mar 31 22:11:15 GMT 2025
Record UNII
R519X5WXUV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESERIDINE HYDROCHLORIDE
Common Name English
ESERIDINE MONOHYDROCHLORIDE
Preferred Name English
1,2-OXAZINO(6,5-B)INDOL-6-OL, 2,3,4,4A,9,9A-HEXAHYDRO-2,4A,9-TRIMETHYL-, METHYLCARBAMATE (ESTER), MONOHYDROCHLORIDE, (4AS-CIS)-
Systematic Name English
GENESERINE HYDROCHLORIDE
Common Name English
Code System Code Type Description
CAS
164713-95-5
Created by admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
PRIMARY
PUBCHEM
86278275
Created by admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
PRIMARY
FDA UNII
R519X5WXUV
Created by admin on Mon Mar 31 22:11:15 GMT 2025 , Edited by admin on Mon Mar 31 22:11:15 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY